Bnp Paribas Asset Management Holding S.A. Madrigal Pharmaceuticals, Inc. Transaction History
Bnp Paribas Asset Management Holding S.A.
- $41 Billion
- Q2 2025
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 132 shares of MDGL stock, worth $45,636. This represents 0.0% of its overall portfolio holdings.
Number of Shares
132Holding current value
$45,636% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MDGL
# of Institutions
365Shares Held
23.2MCall Options Held
979KPut Options Held
432K-
Janus Henderson Group PLC London, X02.21MShares$763 Million0.42% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.1MShares$726 Million39.89% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.02MShares$699 Million10.84% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$689 Million10.82% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$683 Million7.8% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.91B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...